146. Приказ Министерства здравоохранения Российской Федерации от 05.08.2003 г. №330 «О мерах по совершенствованию лечебного питания в лечебно-профилактических учреждениях Российской Федерации».
147. Приказ Министерства здравоохранения Российской Федерации от 21.06.2013 г. № 395н «Об утверждении норм лечебного питания».
148. Приказ Министерства здравоохранения Российской Федерации от 23.09.2020 г. №1008н «Об утверждении порядка обкспечения пациентов лечебным питанием».
149. Wu SY, Short NJ, Nasr L, Dabaja BS, Fang PQ. Central Nervous System Prophylaxis and Treatment in Acute Leukemias. Curr Treat Options Oncol. 2022 Dec;23(12):1829-1844. doi: 10.1007/s11864-022-01032-5. Epub 2022 Dec 13. PMID: 36510037; PMCID: PMC9767998.
150. Hou, C. xiao, Chen, Y., Liu, S. hao, Jiang, Y. zhi, Huang, D. ping, & Chen, S. ning. (2023). Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia. Hematology, 29(1). https://doi.org/10.1080/16078454.2023.2293496
151. Chen, X., Huang, J., Xu, N., Fan, Z., Nie, D., Huang, F., Sun, Q., Zhang, X., Liang, X., Shi, P., Wang, Z., Liu, H., Xu, J., Dai, M., Yu, G., Zhang, Y., Sun, J., Liu, Q. and Xuan, L. (2022), A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer, 128: 2138-2147. https://doi.org/10.1002/cncr.34182
152. Li, Y., Dai, H., Yao, D. et al. Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission. Ann Hematol 101, 1865–1867 (2022). https://doi.org/10.1007/s00277-022-04823-w
153. Liu M, Zhao X, Pan W, et al. A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy. Br J Haematol. 2021; 195(2):e123-e128.
154. Song B, Wang X, Kong X, et al. Clinical response to venetoclax and decitabine in acute promyelocytic leukemia with a novel RARA-THRAP3 fusion: a case report. Front Oncol. 2022; 12:828852.
155. Zhou, Z., Chen, E., Jiang, J., Xue, L., Zhu, L., Hu, X., … Tong, J. (2024). Successfully treatment of PLZF-RARα positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review. Hematology, 29(1). https://doi.org/10.1080/16078454.2024.2399362
156. Zhang G, Song Y, Wan L, et al. Treatment of STAT5b-RARA positive acute promyelocytic leukemia by venetoclax combining with homoharringtonine, cytarabine: a case report and literature review. Blood Sci. 2022; 4(2): 93-96.
157. Li H, Xiang X, Ding H, et al. Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA. Br J Haematol. 2022; 199(5): 768-771.
158. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 1993;12(3):1161-1167.
159. Corey SJ, Locker J, Oliveri DR, et al. A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features. Leukemia. 1994;8(8):1350-1353.
160. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997;17(1):109-113.
161. Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8(9):1741-1749.
162. Catalano A, Dawson MA, Somana K, et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 2007;110(12):4073-4076.
163. Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka M. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica. 2008;93(9):1414-1416.
164. Yamamoto Y, Tsuzuki S, Tsuzuki M, Handa K, Inaguma Y, Emi N. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood. 2010;116(20):4274-4283.
165. Won D, Shin SY, Park C-J, et al. OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia. Blood. 2013;121(8):1432-1435.
166. Chen Y, Li S, Zhou C, et al. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia. Blood. 2014;124(6):936-945.
167. Li J, Zhong H-Y, Zhang Y, et al. GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid. Br J Haematol. 2015;168(6):904-908.
168. Yin CC, Jain N, Mehrotra M, et al. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw. 2015;13(1):19-22.
169. Cheng CK, Wang AZ, Wong THY, et al. FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia. Blood. 2017;129(19):2705-2709.
170. Tsimberidou, AM., Estey, E., Kantarjian, H. et al. Введение фактора стимуляции колоний гранулоцитов, связанное с кровоизлиянием в мозг при остром промиелоцитарном лейкозе. Leukemia 20 , 1452–1453 (2006). https://doi.org/10.1038/sj.leu.2404272
171. Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, Jabbour E, Schiffer CA, Lang A, Ravandi F. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):46-67. doi: 10.3322/caac.21873. Epub 2024 Dec 10. PMID: 39656142; PMCID: PMC11745214.
172. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 Sep 15;125(18):3219-3224. doi: 10.1002/cncr.32196. Epub 2019 May 31. PMID: 31150121.